NEW YORK MAR 14, 2008 (Reuters) - Bevacizumab can cause renal thrombotic microangiopathy secondary to impaired VEGF (vascular endothelial growth factor) signaling within the glomerulus, according to new research published in the March 13th issue of The New England Journal of Medicine.
